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a b s t r a c t
Background: The inactivated Vero cell-derived vaccine (JE-VC, IXIARO) has replaced the traditionalmouse
brain-derived preparations (JE-MB) in travelers’ vaccinations against Japanese encephalitis. We showed
recently that a single JE-VC dose efﬁciently boosts immunity in JE-MB-primed vaccinees, and that JE-
VC elicits cross-protective immunity against non-vaccine genotypes, including the emerging genotype I.
While these studies only provided short-term data, the present investigation evaluates the longevity of
seroprotection in the same volunteers.
Methods: The study comprised 48 travelers who had received (1) JE-VC primary series, (2) JE-MB primary
series followed by a single JE-VC booster dose, or (3) JE-MB primary series and a single JE-MB booster
dose. Serum samples were collected two years after the last vaccine dose, and evaluated with the plaque-
reduction neutralization test against seven Japanese encephalitis virus strains representing genotypes
I–IV. PRNT50 titers≥10 were considered protective.
Results: Two years after the primary series with JE-VC, 87–93% of the vaccinees proved to be cross-
protected against test strains representing genotypes II-IV and 73% against those of genotype I. After a
single homologous or heterologous booster dose to JE-MB-primed subjects, the two-year seroprotection
rates against genotype I–IV strains were 89–100%.
Conclusions: After JE-VC primary series, seroprotection appeared to wane ﬁrst against genotype I. The
ﬁrst booster should not be delayed beyond two years. In JE-MB-primed subjects, a single JE-VC booster
provided cross-protective imm
interval of two years or even lo
JE-VC dose for boosting JE-MB
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Table 1 shows the background characteristics of the study popu-
lation (n=48). The majority were generally healthy adult travelers20 E.O. Erra et al. / Vac
. Introduction
Japanese encephalitis (JE) is the most common arboviral
ncephalitisworldwide. Case-fatality ratesmayamount to30%, and
pproximately half of the survivors suffer from long-lasting seque-
ae [1]. While other control measures have proven insufﬁcient,
ctive immunization remains the best approach in dealing with
he disease burden [2]. Vaccines are recommended for endemic
opulations and travelers at risk [3,4].
In travelers’ vaccinations against JE, the inactivated Vero cell-
erivedvaccine (JE-VC, tradename IXIARO)has largely replaced the
raditional inactivated, mouse brain-derived preparations (JE-MB,
rade names JE-VAX and Japanese Encephalitis Vaccine GCC). The
wo vaccine types are derived from different JE virus (JEV) strains,
A14-14-2 and Nakayama, both of which, however, belong to the
ame JEVgenotype (GIII).We [5] andothers [6]have recently shown
signiﬁcant cross-reactivity between the immune responses to
hese two vaccines: travelers primed with JE-MB do not require
he regular two-dose schedule of JE-VC – one booster dose suf-
ces to elicit protective levels of neutralizing antibodies. No data
xist on the longevity of the response to such heterologous boost-
ng.
Japanese encephalitis viruses are divided into ﬁve genotypes
GI–GV) [7]. All the vaccines currently available are derived from
trains of GIII, formerly the predominant genotype in large areas of
sia [8]. Since the 1990s, however, GI strains have been isolated
t an increasing rate, and in many endemic countries this type
as even replaced GIII as the dominant genotype [8–12]. While
he proportion of strains belonging to the other three genotypes
solated (GII, GIV, GV) has remained smaller [13–15], the emer-
ence of GI has raised the question of the current GIII-vaccines’
ross-protective capacity [10–12]. In our recent study, we showed
hat both JE-VC and JE-MB elicit a protective level of neutralizing
ntibodies against not only the vaccine genotype (GIII) but also
trains belonging to non-vaccine genotypes [16]. However, there
as a special concern associatedwith theGI genotype: even though
rotective levels of antibodies were reached, the titers remained
elatively low, bringing into question the duration of the cross-
rotection.
Thepresent investigationwascarriedout toaddress the issuesof
1) the duration of seroprotection elicited by heterologous boost-
ng, and (2) the longevity of JE vaccine-induced cross-protective
mmunity against non-vaccine JEV genotypes, GI, GII and GIV after
rimary and secondary immunizations.
. Methods
.1. Study population
This study presents two-year follow-up data on the cross-
rotection provided by the two-dose JE-VC primary series for
EV-naïve subjects, and, on the other hand, by a single JE-VC or
E-MB booster dose for those primed with the JE-MB vaccine. The
resent research is a follow-up to two earlier ones exploring the
riming and boosting capacity of the two inactivated Japanese
ncephalitis vaccines, JE-VC and JE-MB, in travelers [5,16]. The two
accines are composed of different JEV strains: the JE-VC prepa-
ation IXIARO is based on the SA14-14-2 strain, while the JE-MB
accine Japanese Encephalitis Vaccine GCC contains the Nakayama
train. Notably, a Beijing-based JE-MB vaccine is not available for
nternational travelers and was thus not included in the present
tudy. The study population consisted of JE vaccinees whose early
mmune responses were reported in the two former studies. In
his follow-up we included subjects who had received (1) a JE-
C primary series (group VC), (2) a JE-MB primary series followed2 (2014) 119–123
by a single booster dose of JE-VC (group MB-VC), and (3) a JE-MB
primary series followed by a single booster dose of JE-MB (group
MB-MB). In the booster groups, the median intervals between pri-
mary and booster vaccinations were 5.2 (range 1.1–20.5) years
(group MB-VC) and 3.7 (range 1.0–12.2) years (group MB-MB).
Eligibility criteria for the participants have been described pre-
viously [5,16]. Brieﬂy, the subjects were adult volunteers who
received JE primary or booster vaccination as part of their pre-
travel consultation at two travel clinics in Finland and Sweden.
The following exclusion criteria were used: age <18 years, acute
disease at the time of enrollment, pregnancy or lactation, clini-
cally signiﬁcant immunosuppression, known history of JE, alcohol
or drug abuse, or suspected hypersensitivity to any of the vaccine
components.
The initial study comprised 31 volunteers in group VC, 42 in
MB-VC and 32 in MB-MB [5]. For this research project, we collected
follow-up serum samples from all volunteers available around two
years after their last vaccinedose: 15/31participants (48%) in group
VC, 19/42 (45%) in group MB-VC, and 14/32 (44%) in group MB-MB.
The samples were evaluated for persistence and cross-reactivity
of the JEV neutralizing antibodies. Of the subjects in the JE-VC pri-
mary vaccination group (groupVC), only thosewere included in the
analyses who showed no antibodies against the JEV strains prior to
administering the vaccine series.
The study (EudraCT: 2010-023300-27) was approved by the
appropriate ethics committees and registered in the databases
required. All volunteers provided informed consent.
2.2. Determination of the neutralizing antibody responses
Titers of neutralizing antibodies were determined by the
plaque-reduction neutralization test (PRNT), which is currently
regarded the method of choice for assessment of seroprotection
elicited by JE vaccines [17]. The neutralization tests were per-
formed as described previously [5,18]. All serum samples were
tested against seven different JEV strains representing geno-
types I–IV: SM-1 (GI; isolated in Thailand 2002), 1991 (GI; Korea
1991), B 1034/8 (GII; Thailand 1983), Nakayama (GIII; Japan 1935,
strain in JE-MB), SA14-14-2 (attenuated GIII strain, strain in JE-
VC; parental strain China 1954), Beijing-3 (GIII, China 1949),
and 9092 (GIV; Indonesia 1981). The analyses were performed
in a blinded manner. A PRNT50 titer (reciprocal of the test
serum dilution that reduces the virus plaque count by 50% com-
pared to a virus-only control) ≥10 was considered protective
[17,2].
2.3. Statistics
Statistical analyses were performed with the R 2.13.0 software
(R Development Core Team 2011). Two-sided 2 tests and two-




3.1. Study group of Finnish and Swedish travelersof Finnish or Swedish origin, median age 35 years (range 21–71
years). 41% (20/49) of the subjects had received a yellow fever (YF)
vaccine in the past, and 18% (9/49) reported tick-borne encephalitis
(TBE) vaccination.
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Table 1
Background characteristics of the 48 travelers volunteering in the follow-up study.
Characteristic Group VC (n=15) Group MB-VC (n=19) Group MB-MB (n=14)
Age, years, median (range) 30 (21–71) 41 (21–67) 36 (22–65)
Sex
Male 5 (33%) 7 (37%) 6 (43%)
Female 10 (67%) 12 (63%) 8 (57%)
Ethnic origin
Finnish/Swedish 15 (100%) 18 (95%) 13 (93%)
Other 0 (0%) 1 (5%) 1 (7%)
Chronic diseases 1 (7%) 3 (16%) 1 (7%)
Time since preceding JE vaccine dose, years
Mean (SD) 2.1 (0.1) 2.1 (0.3) 2.2 (0.3)
Previous vaccinations against other ﬂaviviruses
TBE vaccination 3 (20%) 6 (32%) 0 (0%)


































mPrevious dengue infection 0 (0%)
bbreviations: JE, Japanese encephalitis; TBE, tick-borne encephalitis; YF, yellow fev
.2. Long-term seroprotection shown in the analyses of
eutralizing antibodies
Fig. 1 shows both the individual PRNT50 titers and their geomet-
ic means for the various vaccination groups as tested against each
f the seven JEV test strains two years after the last vaccine dose.
he rates of seroprotection against the test strains are displayed in
able 2. No signiﬁcant differenceswere found in the seroprotection
ates against the various test strains within each study group.
Of the subjects primed two years earlier with JE-VC (n=15), 93%
ad protective levels of neutralizing antibodies against the vaccine
train SA14-14-2, and 87% against the other two GIII test strains at
ollow-up (Table 2). The seroprotection rates against the test strains
f heterologous genotypes were 73% (GI), 93% (GII), and 87% (GIV)
Table 2). The geometric mean titers (GMTs) against the various
trains ranged between 24 and 62 (Fig. 1).
Of those primed with JE-MB and subsequently boosted with a
ingle JE-VC dose (n=19), 100% showed protective levels of neu-
ralizing antibodies against the three GIII test strains at follow-up
Table 2). The seroprotection rates against the test strains of other
enotypeswere 89% (GI) and95% (GII andGIV strains) (Table 2). The
MTs varied between 95 and 239 (Fig. 1). Notably, a representative
f genotype V was not available for testing. However, as long as GV
emains such a rare cause of encephalitis, this genotype appears to
e of minor clinical signiﬁcance.
Of the subjects primed and boosted with JE-MB (n=14), 93%
isplayed protective antibody titers against the GIII test strains at
ollow-up (Table 2). The respective seroprotection rates against test
trains of heterologous genotypes were 93% (GI) and 100% (GII and
IV) (Table 2). The GMTs recorded against the various test strains
anged between 101 and 582 (Fig. 1). No signiﬁcant differences
ere found in the seroprotection rates between the booster groups.
able 2
eroprotection rates at two years’ follow-up. Seroprotection rates are given after a
wo-year follow-up for three vaccination groups: primary immunization with two
oses of JE-VC (group VC), booster immunization of JE-MB primed volunteers with
ne dose of JE-MB (group MB-MB) or JE-VC (group MB-VC).
Test strains Group VC Group MB-VCa Group MB-MB
GI (SM-1) 73% (11/15) 89% (16/18) 93% (13/14)
GI (1991) 73% (11/15) 89% (17/19) 93% (13/14)
GII (1034/8) 93% (14/15) 95% (18/19) 100% (14/14)
GIII (SA14-14-2) 93% (14/15) 100% (18/18) 93% (13/14)
GIII (Nakayama) 87% (13/15) 100% (18/18) 93% (13/14)
GIII (Beijing-3) 87% (13/15) 100% (19/19) 93% (13/14)
GIV (9092) 87% (13/15) 95% (18/19) 100% (14/14)
a The volume of the serum sample from one volunteer did not sufﬁce for deter-
ining the neutralizing antibodies against all test strains.1 (5%) 0 (0%)
4. Discussion
While recent data prove that a single JE-VC dose efﬁciently
boosts immunity in JE-MB-primed travelers [5,6], and that both JE-
MB and JE-VC induce cross-protection to non-vaccine genotypes
[16], the question of the duration of immunity has remained unan-
swered. Exploring antibody responses after a two-year follow-up,
the present study is the ﬁrst to provide data on the longevity of the
cross-protective capacity of JE-VC.
4.1. Duration of seroprotection after primary series with JE-VC
Themajority (93%) of vaccineeswere found to have neutralizing
antibodies against the vaccine strain two years after receiving the
JE-VC primary series. The longevity of the neutralizing antibodies
against the vaccine strain has been investigated before [19–21].
In these studies a somewhat shorter duration of seroprotection
was shown for JE-VC; the current recommendation therefore is
to give a booster dose at 12–24 months after the primary series
[22]. The lowest seroprotection was observed in a study reporting
a rate of 58% one year and 48% two years after JE-VCprimary immu-
nization [20]. In another study, 69% of the subjects were found to
be seroprotected at 15 months [21], while a third one reported
a seroprotection rate of 83% at one year [19]. Such differences in
long-term seroprotection have been associated with variations in
the subjects’ TBE vaccination status [20]. In the present investiga-
tion, approximately half of the primary vaccinees had previously
received a TBE or YF vaccine. The seroprotection rates proved high
in subjects bothwith andwithout a history of other ﬂaviviral vacci-
nations. Unfortunately, the limited number of participants did not
allow speciﬁc analyses of the potential effect of TBE/YF vaccines on
JE vaccination responses. However, these data suggest that a min-
imum booster interval of two years can be considered at least for
those immunized with other ﬂaviviral vaccines, and possibly also
for the vaccine-naive.
The emergence of heterologous JEV strains and genotypes has
raised aquestionof the current JE vaccines’ capacity to confer cross-
protection against circulating strains of non-vaccine genotypes
[10–12]. In the present study, the majority of JE-VC-primed travel-
ers showed protective levels of neutralizing antibodies against the
six heterologous test strains representing genotypes GI–GIV at the
two-year follow-up. The seroprotection rates against GI appeared
lower than those against the other test strains (GII–GIV), yet these
differences did not reach statistical signiﬁcance. With respect to
genotypes GII, GIII and GIV our data suggest an opportunity to
extend the interval between primary series and ﬁrst booster even
longer than 24 months. This recommendation would, however, not
be justiﬁed in light of the observation that only 73% of the vaccinees
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Fig. 1. PRNT50 titers at two years’ follow-up. PRNT50 titers are given after a two-year
follow-up for three vaccination groups: primary immunization with two doses of
JE-VC (group VC), booster immunization of JE-MB primed volunteers with one dose
of JE-MB (groups MB-MB) or JE-VC (group MB-VC). Dots represent individual titers
against the various Japanese encephalitis virus test strains, and the short lines their
geometric means. Data are given separately for each study group. The long solid line
indicates the threshold for seroprotection (a PRNT50 titer of 10).2 (2014) 119–123
were seroprotected against GI after primary immunization with
JE-VC; in fact, even a two-year interval could hence be criticized.
4.2. Duration of seroprotection after booster vaccination
The recent data proving that a single dose of JE-VC will sufﬁce
to elicit short-term protective response in JE-MB-primed travelers
[5,6] has prompted some countries, such as Finland, to revise their
national recommendations accordingly [23]. Until now, however,
no data have been provided on protection duration.
In the present study, neutralizing antibodies against the vaccine
strains were found in all JE-MB-primed volunteers two years after
the single booster dose of heterologous JE-VC. Besides seroprotec-
tion against the vaccine strains, the vast majority of volunteers also
showed neutralizing antibodies against the ﬁve heterologous test
strains of GI–GIV. The seroprotection rates after the heterologous
JE-VC boosterwere comparablewith those recorded after a booster
vaccine homologous to the primary series. It is noteworthy that,
in contrast to the varying seroconversion rates observed after the
JE-VC primary series, the cross-protection rates for JE-MB-primed
subjects were around 90% both after a homologous and a heterolo-
gous booster. Taken together, these results further support the use
of a single dose of JE-VC for boosting JE-MB immunity, suggesting
that the interval to a second booster dose may be extended to two
years or even longer. No data, however, exist as yet on the longevity
of cross-protection beyond two years.
5. Conclusions
Among travelers primed with JE-VC, seroprotection against the
vaccine strain lasted for at least two years, and most vaccinees also
proved to be protected against the non-vaccine JEV genotypes at
follow-up. Yet the seroprotection rates against the emerging geno-
type, GI, were no higher than 73%, suggesting that the booster
vaccination should not be delayed beyond two years.
As for travelers with a history of JE-MB primary series, a single
doseof JE-VCprovidedcross-reactive seroprotectionagainst strains
of all major genotypes, including GI, for at least two years after the
booster. This further encourages the use of a single heterologous
JE-VC dose for boosting JE-MB immunity. While our results suggest
that the next booster dose can be administered even after the pre-
scribed 24-month interval, new studies are needed to establish the
optimal timing.
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